Rabies vaccine - Yisheng Biopharma

Drug Profile

Rabies vaccine - Yisheng Biopharma

Alternative Names: PIKA adjuvant-based rabies vaccine - Yisheng Biopharma; PIKA rabies vaccine - Yisheng Biopharma

Latest Information Update: 06 Jan 2017

Price : $50

At a glance

  • Originator Yisheng Biopharma
  • Developer Duke-NUS Graduate Medical School Singapore; Yisheng Biopharma
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Rabies
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Rabies

Most Recent Events

  • 04 Jan 2017 Clinical trials in Rabies in USA (IM)
  • 04 Jan 2017 Rabies vaccine - Yisheng Biopharma receives Orphan Drug status for Rabies in USA
  • 01 Oct 2016 Yisheng Biopharma completes a phase II trial in Rabies (Prevention, In volunteers) in Singapore (IM) (NCT02956421)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top